PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...

BriaCell Therapeutics shares are trading lower by 40% Thursday afternoon. The company announced the pricing of a $5.5 million ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months ...

BriaCell Therapeutics (BCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily ...

BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, Thursday announced the pricing of an underwritten public ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale ...

Briacell Therapeutics Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.03%. The profit margin, also known as the revenue ratio or gross profit ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety Monitoring Board ...

Equities researchers at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a ...

Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for BriaCell Therapeutics in a report ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...